Home > Riviste > Minerva Ginecologica > Fascicoli precedenti > Articles online first > Minerva Ginecologica 2020 Nov 03

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

 

Minerva Ginecologica 2020 Nov 03

DOI: 10.23736/S0026-4784.20.04691-2

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

The role of sentinel-node biopsy in ovarian cancer

Pawel MACH, Rainer KIMMIG, Paul BUDERATH

West German Cancer Center, Department for Gynaecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany


PDF


Lymph node involvement is an important prognostic factor in early and advanced epithelial ovarian cancer (eoc). However, to date there is no reliable method of detecting lymph node involvement, apart from surgical staging. Thus, pelvic and paraaortic lymphadenectomy (lNe) are still part of standard surgery of early ovarian cancer. There is conflicting evidence about the therapeutic value of systematic lNe in early eoc. Thus, the developmemt of a method to predict nodal status accurately, without extensive lNe, is the subject of ongoing research. Sentinel lymphadenectomy (SlN) has become a standard procedure in oncological surgery. However, SlN is not yet an established and widely accepted pro-cedure for eoc. This review aimed at summarizing available evidence on its feasibility and reliability in eoc. overall, evidence of SlN in early eoc is still scarce. So far, only small series of patients with a variety of tracers and injection sites were published. From the available literature, the most promising technique seems to be injection into the infundibu-lopelvic, as well as the proper ovarian ligament. indocyanine green seems to be an excellent tracer for successful SlN of ovarian tumors, which can be used during laparoscopic or robotic surgery. The detection rates and true positive rates of studies support further investigation of the technique. Results from prospective studies, e.g. the ongoing SellY trial, are necesssary to implement SlN into the standard treatment of early EOC.


KEY WORDS: Carcinoma, ovarian epithelial; Sentinel lymph node; Neoplasms

inizio pagina